Evidence mapPaperPMID 40344246Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025

PTPN2 Negatively Regulates Macrophage Immune Responses and Cellular Bioenergetics.

Valerie Vinette, Yevgen Zolotarov, Alexandre Poirier, Zuzet Martinez Cordova, Isabelle Aubry, Michel L Tremblay

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Valerie VinetteDepartment of Biochemistry, McGill University, Montreal, Canada.ORCID https://orcid.org/0000-0002-8494-9664
Yevgen ZolotarovDepartment of Biochemistry, McGill University, Montreal, Canada.
Alexandre PoirierRosalind and Morris Goodman Cancer Institute, McGill University, Montreal, Canada.
Zuzet Martinez CordovaDepartment of Biochemistry, McGill University, Montreal, Canada.
Isabelle AubryDepartment of Biochemistry, McGill University, Montreal, Canada.
Michel L TremblayDepartment of Biochemistry, McGill University, Montreal, Canada.ORCID https://orcid.org/0000-0002-0281-541X

Funding

Canadian Government | Canadian Institutes of Health Research (CIHR) FDN-159923Fondation Jean-Louis Lévesque (Fondation J Louis Levesque)FRQ | Fonds de Recherche du Québec - Santé (FRQS)Terry Fox Foundation (La Fondation Terry Fox) TFF-116128
6 · The paper itself

Abstract

PTPN2 is encoded by the protein tyrosine phosphatase N2 (also known as TC-PTP) and is a negative regulator of cytokine signaling and macrophage differentiation. In the past decade, our work and others, including several pharmaceuticals, have emphasized that inhibition of PTPN2 and PTPN1 (also known as PTP1B) may act as a new first-of-class cancer immunotherapeutic. Although the potential roles of these two enzymes in various immune cells have been broadly reported, the specific activity of PTPN2 in regulating macrophage immune and metabolic responses has yet to be fully elucidated. Hence, we sought to investigate the function of PTPN2 in macrophage polarization and on their activities. We used two different mouse models to systematically and specifically inhibit the expression of PTPN2 in macrophages and utilized a chemical inhibitor with a macrophage human cell line to assess their immune and metabolic profiles. We demonstrated that PTPN2 ablation in macrophages alters their immunometabolic transcriptome and enhances their proinflammatory response, as observed by increased IFN-ɣ and nitric oxide production. PTPN2 deficiency also leads to a dysregulation of mitochondrial respiration, as observed by decreased oxygen consumption and ATP production. We establish herein that PTPN2 dampens the proinflammatory response of macrophages while altering their mitochondrial respiration, validating its macrophage inhibition as a contributing factor in the potency of systemic dual inhibition of PTPN1 and PTPN2 against cancer.

Indexed as

Energy MetabolismMacrophagesProtein Tyrosine Phosphatase, Non-Receptor Type 2AnimalsHumansMiceMice, Inbred C57BLMice, KnockoutNitric OxideNitric OxideProtein Tyrosine Phosphatase, Non-Receptor Type 2Ptpn2 protein, mouseLysM‐Cremacrophagesproinflammationprotein tyrosine phosphatasesPTPN1PTPN2

Identifiers

PMID40344246
PMCPMC12063717

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.